Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 26 04:00PM ET
1.05
Dollar change
+0.20
Percentage change
23.70
%
Index- P/E- EPS (ttm)-9.59 Insider Own9.96% Shs Outstand27.21M Perf Week26.51%
Market Cap28.57M Forward P/E- EPS next Y-2.06 Insider Trans0.00% Shs Float24.50M Perf Month14.50%
Income-122.42M PEG- EPS next Q-0.59 Inst Own47.62% Short Float2.61% Perf Quarter-23.36%
Sales0.02M P/S1428.52 EPS this Y-26.33% Inst Trans7.56% Short Ratio1.03 Perf Half Y-61.11%
Book/sh-5.07 P/B- EPS next Y74.58% ROA-251.08% Short Interest0.64M Perf Year-65.35%
Cash/sh0.46 P/C2.27 EPS next 5Y- ROE- 52W Range0.76 - 6.70 Perf YTD-22.22%
Dividend Est.- P/FCF- EPS past 5Y48.29% ROI- 52W High-84.33% Beta0.94
Dividend TTM- Quick Ratio0.28 Sales past 5Y126.71% Gross Margin-3211.11% 52W Low38.89% ATR (14)0.09
Dividend Ex-Date- Current Ratio0.28 EPS Y/Y TTM44.56% Oper. Margin-375416.67% RSI (14)59.36 Volatility12.33% 9.18%
Employees54 Debt/Eq- Sales Y/Y TTM-97.52% Profit Margin-680133.33% Recom1.00 Target Price27.80
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-614.96% Payout- Rel Volume1.05 Prev Close0.85
Sales Surprise- EPS Surprise-428.65% Sales Q/Q-100.00% EarningsNov 13 AMC Avg Volume619.02K Price1.05
SMA2019.41% SMA50-3.24% SMA200-57.62% Trades Volume652,768 Change23.70%
Today 08:00AM
Feb-08-24 08:00AM
Jan-22-24 08:00AM
Jan-16-24 08:00AM
Jan-08-24 08:00AM
08:00AM Loading…
Jan-02-24 08:00AM
Dec-19-23 08:00AM
Dec-18-23 08:00AM
Dec-11-23 08:00AM
Dec-01-23 07:41AM
Nov-30-23 04:48PM
Nov-14-23 09:37AM
07:01AM
Nov-13-23 04:05PM
Nov-06-23 08:00AM
04:05PM Loading…
Oct-30-23 04:05PM
Oct-23-23 05:30PM
Oct-18-23 05:25AM
Oct-05-23 08:00AM
Sep-25-23 08:00AM
Sep-22-23 05:00AM
Sep-19-23 08:00AM
Sep-11-23 08:01AM
Sep-05-23 08:00AM
Aug-14-23 04:01PM
Aug-03-23 08:00AM
Aug-02-23 08:00AM
Jul-27-23 08:00AM
Jul-17-23 06:00AM
Jul-05-23 08:00AM
08:30AM Loading…
Jun-28-23 08:30AM
Jun-26-23 06:00AM
Jun-14-23 04:05PM
Jun-13-23 08:00AM
Jun-08-23 09:00AM
May-24-23 08:00AM
May-17-23 01:53PM
May-16-23 05:44AM
May-15-23 04:05PM
May-08-23 09:00AM
May-01-23 09:00AM
Apr-20-23 04:46PM
Apr-05-23 07:46PM
Mar-30-23 04:01PM
Mar-23-23 09:00AM
Feb-23-23 09:00AM
Feb-16-23 09:40AM
09:00AM
Feb-02-23 09:55AM
Jan-19-23 04:05PM
Jan-09-23 09:00AM
Dec-30-22 09:00AM
Dec-08-22 04:05PM
Nov-29-22 09:00AM
Nov-17-22 05:37AM
Nov-14-22 05:35PM
04:01PM
Nov-07-22 04:15PM
08:06AM
Oct-27-22 09:00AM
Oct-25-22 09:00AM
Oct-24-22 09:00AM
Oct-19-22 09:00AM
Oct-10-22 09:00AM
Sep-13-22 09:00AM
Sep-07-22 09:00AM
Sep-06-22 06:30AM
Aug-15-22 04:05PM
Aug-12-22 09:30AM
Aug-10-22 09:00AM
Aug-08-22 09:00AM
Aug-03-22 09:00AM
Jul-26-22 09:00AM
Jul-14-22 09:00AM
Jul-07-22 09:00AM
Jun-22-22 09:00AM
May-31-22 09:00AM
May-25-22 09:00AM
May-19-22 09:00AM
May-16-22 04:30PM
May-10-22 04:01PM
Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.